A collaboration agreement with Belina was signed in 2017 with the aim of using LIDDS depot technology in combination with a drug intended for the treatment of breast cancer. The collaboration has now concluded.
LIDDS has delivered the drug formulations with release profiles in line with Belina's requests. Due to increased requirements for the drug's dosing level, Belina has chosen not to continue with the collaboration.
-We have fulfilled our obligations and LIDDS has had full cost coverage for the collaboration. The collaboration has concluded as the dosing levels required have be adjusted and increased during the project, says Monica Wallter, CEO LIDDS.
For more information, please contact:
Monica Wallter, CEO LIDDS, +46 (0)737 07 09 22, monica.wallter@liddspharma.com
LIDDS is required to disclose the information in this press release under the European Union's Market Abuse Regulation. The information was submitted through the agency of the aforementioned contact person for publication on 7 March 2019 at 13.45 CET.
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid is superior to any drug delivery technology in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in preclinical phase for cytostatics and immunoactive agents. LIDDS (LIDDS) shares are listed on Nasdaq First North. Redeye AB, Certifiedadviser@redeye.se, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit www.liddspharma.com
